DelveInsight has launched a new report on Huntington's Disease Market Insights, Epidemiology and Market Forecast-2030
"Huntington's Disease Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Huntington's Disease market. A detailed picture of the Huntington's Disease pipeline landscape is provided, which includes the disease overview and Huntington's Disease treatment guidelines. The assessment part of the report embraces in-depth Huntington's Disease commercial assessment and clinical assessment of the Huntington's Disease pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington's Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Huntington’s disease is a hereditary neurodegenerative disorder caused by mutation in the HTT genes. The HTT mutation that causes Huntington disease involves a DNA segment known as a CAG trinucleotide repeat. This segment is made up of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear multiple times in a row.
Request for :- Pipeline free sample page
Huntington's Disease of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Huntington's Disease with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Huntington's Disease treatment.
- Huntington's Disease key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Huntington's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Huntington's Disease Analytical Perspective by DelveInsight
- In-depth Huntington's Disease Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Huntington's Disease Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Huntington's Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Huntington's Disease across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Huntington's Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Huntington's Disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Huntington's Disease.
Major key companies are working on Huntington's Disease which are given below:-
1. ROCHE Pharma Co.
2. EIP Pharma Co.
Name of covered drugs are given below:-
1. RG6042 (RO7234292)
2. Neflamapimod
1. Report Introduction
2. Huntington's Disease
2.1. Overview
2.2. History
2.3. Huntington's Disease Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Huntington's Disease Diagnosis
2.6.1. Diagnostic Guidelines
3. Huntington's Disease Current Treatment Patterns
3.1. Huntington's Disease Treatment Guidelines
4. Huntington's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
6. Huntington's Disease Late Stage Products (Phase-III)
7. Huntington's Disease Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Huntington's Disease Discontinued Products
13. Huntington's Disease Product Profiles
14. Huntington's Disease Key Companies
15. Huntington's Disease Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Huntington's Disease Unmet Needs
18. Huntington's Disease Future Perspectives
19. Huntington's Disease Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About Delveinsight
Related Reports:
1. Huntington's Disease - Epidemiology Forecast to 2030
2. Huntington's Disease- Market Insight, Epidemiology and Market Forecast -2030
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
